[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634159":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":76,"collaborators":30,"id":78,"slug":30,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":30,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":30,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":64,"whyStopped":30,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Sarepta Therapeutics, Inc.","INDUSTRY",[8,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: SRP-1005 Dose 1","EXPERIMENTAL","Participants will receive SRP-1005 or placebo.",[13,14],"Drug: SRP-1005","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 2: SRP-1005 Dose 2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Cohort 3: SRP-1005 Dose 3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Cohort 4: SRP-1005 Dose 4",[13,14],[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","SRP-1005","Subcutaneous injection",[9,16,19,22],null,{"type":26,"name":32,"description":28,"armGroupLabels":33,"otherNames":30},"Placebo",[9,16,19,22],[35],{"name":36,"affiliation":5,"role":37},"Medical Director","STUDY_DIRECTOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":30,"email":43},"Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4","CONTACT","1-888-SAREPTA (1-888-727-3782)","SareptAlly@sarepta.com",[45,62],{"facility":46,"status":47,"city":48,"state":30,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Pacific Clinical Research Network - Auckland (PCRN Auckland)","NOT_YET_RECRUITING","Auckland","622","New Zealand",{"type":52,"coordinates":53},"Point",[54,55],174.76349,-36.84853,{"lat":55,"lon":54},[58,59],{"name":30,"role":41,"phone":30,"phoneExt":30,"email":43},{"name":60,"role":61,"phone":30,"phoneExt":30,"email":30},"Richard Roxburgh, FRACP, PHD","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":64,"city":65,"state":30,"zip":66,"country":50,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"New Zealand Brain Research Institute","RECRUITING","Christchurch","8014",{"type":52,"coordinates":68},[69,70],172.63333,-43.53333,{"lat":70,"lon":69},[73,74],{"name":30,"role":41,"phone":30,"phoneExt":30,"email":43},{"name":75,"role":61,"phone":30,"phoneExt":30,"email":30},"Timothy Anderson, MD, FRACP",{"type":77,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100634159",false,"NCT07536061","A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease","A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)","Key Inclusion Criteria:\n\n* Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40.\n* Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3.\n* Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study.\n\nKey Exclusion Criteria:\n\n* Any condition that would compromise the safety or feasibility of lumbar puncture or magnetic resonance imaging (MRI).\n* Presence of other significant neurological or systemic illnesses.\n* Current, chronic or active human immunodeficiency virus, hepatitis B\u002FC.\n* Recent use of investigational agents or HTT-lowering therapies.\n* Uncontrolled psychiatric illness or substance use disorders.\n* Pregnancy or lactation.\n\nNote: Other inclusion\u002Fexclusion criteria apply.","ALL","21 Years","70 Years",{"count":88,"type":89},32,"ESTIMATED","INTERVENTIONAL",[92],"PHASE1","This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).",[95],"Huntington's Disease",[97,27,98,99],"Huntington's disease","Dose Escalation","First in Human","2026-06-03",{"date":102,"type":103},"2026-06-04","ACTUAL",{"date":105,"type":103},"2026-05-12",{"date":107,"type":89},"2027-11-30",{"name":5,"class":6},2]